Metrics as of 10/15/2026, 02:16 AM (Berlin time), refresh in progress.
Caris Life Sciences Stock
Caris Life Sciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- David Dean Halbert
- Employees
- 1,846
- Market cap
- $8.8 B
- IPO
- 18/06/2025
Caris Life Sciences, Inc. operates as a leading TechBio firm within the Healthcare sector and the Biotechnology industry. Headquartered in Irving, USA, the company utilizes artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Caris Life Sciences stock: price history
1D
+2.9%
1W
+13.3%
1M
+9.3%
6M
+52.7%
YTD
+15.5%
1Y
-0.0%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~95% stronger price swings than usual
Ask the agents about Caris Life Sciences
Analyst assessment of Caris Life Sciences
PRICE TARGET LOW
US$22.00
CONSENSUS
US$27.25
MEDIAN
US$27.00
PRICE TARGET HIGH
US$33.00
0
STRONG BUY
7
BUY
1
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 14/10/2026
Caris Life Sciences stock metrics
P/E
83.5
P/B
14.85
EV/EBITDA
49.45
RETURN ON EQUITY
-0.1%
NET MARGIN
-0.2%
DEBT/EQUITY
0.76
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
4.0%
FLOAT SHARES
11,294,780
AVG. DAILY VOLUME (30D)
4,794,753
Insider transactions (SEC)
Denton John Russel
Brille Brian J
Brille Brian J
Spetzler David Baxley
Spetzler David Baxley
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +2.9%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Caris Life Sciences stock
What does Caris Life Sciences do?
Caris Life Sciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is David Dean Halbert, the company employs around 1,846 people.
The IPO was on 18/06/2025; the stock trades on NASDAQ under the ticker CAI.
What do analysts say about Caris Life Sciences stock?
8 analysts rate the stock, the consensus is Buy (as of 14/10/2026).
The average price target is US$27.25, ranging from US$22.00 to US$33.00, with a median of US$27.00.
This is an external assessment, not a statement by Market Jury.
When does Caris Life Sciences report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 95% stronger than usual.
Does Caris Life Sciences pay a dividend?
No, Caris Life Sciences currently does not pay a dividend.
Which stocks are comparable to Caris Life Sciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Caris Life Sciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Caris Life Sciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.